Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREFRIN-A vs TYZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.
Temporary relief of nasal congestion,Fever reduction,Mild to moderate pain relief
Symptomatic relief of nasal congestion due to common cold, sinusitis, or allergic rhinitis,Off-label: relief of eustachian tube congestion
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Terminal elimination half-life is approximately 3-4 hours; clinically, this supports dosing every 8-12 hours.
Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI.
Primarily hepatic metabolism via oxidation and reduction pathways; no specific CYP enzymes identified.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Renal elimination of unchanged drug and metabolites accounts for approximately 50% of the dose; fecal elimination is minimal.
Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin.
Approximately 50% bound to plasma proteins, primarily albumin.
Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution).
Approximately 1.5 L/kg, indicating extensive tissue distribution beyond plasma volume.
Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism.
Intranasal: approximately 100% (local effect); systemic bioavailability is low due to local vasoconstriction limiting absorption.
No dosage adjustment required for renal impairment.
No dose adjustment required.
No dosage adjustment required for hepatic impairment.
No dose adjustment required.
Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended.
Children 6-12 years: Instill 1-2 drops of 0.05% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day. For children under 6: Not recommended.
Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency.
Use with caution due to increased sensitivity and risk of adverse effects; consider lower concentration (0.05%) and limit duration of use to 3-5 days.
None.
None
Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors.
Rebound congestion (rhinitis medicamentosa) with prolonged use,Potential for systemic effects with excessive use (hypertension, palpitations),Use caution in cardiovascular disease, hypertension, hyperthyroidism, diabetes, and glaucoma
Hypersensitivity to phenylephrine, acetaminophen, or any excipients. Severe hypertension or coronary artery disease. Concomitant use or within 14 days of MAO inhibitors.
Known hypersensitivity to tetrahydrozoline,Angle-closure glaucoma,Concurrent use with MAO inhibitors or within 14 days of discontinuation
Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration.
None known. No specific dietary restrictions.
Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk.
Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no known teratogenicity but risk of maternal hypertension and reduced placental perfusion.
Phenylephrine: minimal excretion in breast milk; M/P ratio unknown. Pyrilamine: not known if excreted. Antihistamines may cause drowsiness or irritability in infant. Avoid if possible due to lack of safety data. Consider alternative with more data.
No data on excretion in breast milk; M/P ratio unknown. Consider risk of infant systemic effects (tachycardia, hypertension) given vasoconstrictor properties. Only use if clearly indicated and monitor infant for adverse effects.
No specific dose adjustment recommendations due to lack of pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Consider alternative agents if possible.
No specific pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Avoid systemic absorption (e.g., nasal spray for local effect). No dose adjustment recommended based on available evidence.
Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children.
Tyzine (tetrahydrozoline) is an imidazoline derivative with alpha-adrenergic agonist activity. It causes vasoconstriction of conjunctival blood vessels but may produce rebound hyperemia, mydriasis, and systemic effects if overused. Avoid in narrow-angle glaucoma. Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, or diabetes. Do not use longer than 72 hours to prevent rebound congestion. Contact lens wearers should remove lenses before instillation. Do not use in patients with MAOI therapy or within 14 days of discontinuation.
Use exactly as directed; do not use for more than 3 days to avoid rebound congestion.,Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants.,Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor.,Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat.,Store at room temperature away from moisture and heat. Keep out of reach of children.
Do not use more than the recommended dose or for longer than 3 days.,Remove contact lenses before using drops and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not share the medication with others.,If you experience eye pain, vision changes, or redness lasting >72 hours, stop use and consult a doctor.,Do not use if pregnant or breastfeeding without medical advice.,Keep out of reach of children; accidental ingestion may cause serious side effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREFRIN-A vs TYZINE, answered by our medical review team.
PREFRIN-A is a Ophthalmic Decongestant/Antihistamine Combination that works by PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.. TYZINE is a Ophthalmic Decongestant that works by Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREFRIN-A and TYZINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREFRIN-A is: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.. The standard adult dose of TYZINE is: Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREFRIN-A and TYZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREFRIN-A is classified as Category C. Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction . TYZINE is classified as Category C. Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.